Skip to main content
Terug
Watch Compare
IVA logo

Inventiva S.A.

Datakwaliteit: 17%
Ook genoteerd als IVEVF OTC
IVA
Nasdaq Manufacturing Chemicals
€ 5,48
▲ € 0,18 (3,40%)
Marktkapitalisatie: 1,14 B
Company Details · Pierre Broqua
CEO: Pierre Broqua Employees: 114 IPO: May 07, 2019 Website

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Prijs
€ 5,48
Marktkapitalisatie
1,14 B
Dagbereik
€ 5,16 — € 5,67
52-Weeksbereik
€ 2,85 — € 7,98
Volume
233.901
Openen € 5,22
50D / 200D Gem.
€ 6,20
11,58% below
50D / 200D Gem.
€ 4,95
10,65% above

Quick Summary

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A

Waardering

P/E Ratio
N/A
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E — -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) N/A
ROE N/A ROA N/A
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) N/A
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover N/A
Working Capital N/A Tangible Book Value N/A
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio N/A Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield N/A
Market Cap 1,14 B Enterprise Value N/A
Per Share
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share N/A OCF / Share N/A
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion N/A
SBC-Adj. FCF N/A Growth Momentum N/A